Atormac
brintellex
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1863  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,345 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Conclusions
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed64    
    Printed0    
    Emailed0    
    PDF Downloaded46    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2020  |  Volume : 68  |  Issue : 7  |  Page : 154-160

Sellar Pathologies Mimicking Pituitary Tumors


Department of Neurosurgery, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra, India

Date of Web Publication24-Jun-2020

Correspondence Address:
Dr. Chandrashekhar E Deopujari
Department of Neurosurgery, Bombay Hospital Institute of Medical Sciences, Mumbai, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.287682

Rights and Permissions

 » Abstract 


The most common sellar pathology that merits neurosurgical attention is the pituitary adenoma. However, some developmental, inflammatory, and neoplastic lesions may primarily or secondarily involve the sella, mimicking pituitary tumors. Advances in imaging and endocrinological assessment have helped in the recognition of these less common sellar, supra sellar pathologies, which may occasionally create confusion in management. The most common developmental anomaly is the Rathke's cleft cyst and an increasingly recognized inflammatory pathology is the spectrum of hypophysitis. Neoplasms, viz. Craniopharyngioma, Germinoma, Langerhans's cell histiocytosis or metastasis, have more distinctive features in various age groups and are more likely to be correctly diagnosed on current imaging and managed accordingly. This review looks at mainly intraparenchymal pathologies, namely Rathke's Cleft Cyst and various hypophysitides, and will discuss their management strategies.


Keywords: Endocrine dysfunction, Endoscopic endonasal surgery, hypophysitis, pituitary adenoma, Rathke cleft cyst, sella
Key Message: Rathke cleft cyst (RCC) and hypophysitis, though rare, can cause difficulty in diagnosis and management of these masses. A better understanding of their presentation, imaging characteristics and resultant endocrine dysfunction may allow a correct diagnosis in many cases today. However, the occasional patient may require surgery for confirmation of diagnosis and rarely needs decompression for the mass effect on visual apparatus.


How to cite this article:
Karmarkar VS, Deopujari CE. Sellar Pathologies Mimicking Pituitary Tumors. Neurol India 2020;68, Suppl S1:154-60

How to cite this URL:
Karmarkar VS, Deopujari CE. Sellar Pathologies Mimicking Pituitary Tumors. Neurol India [serial online] 2020 [cited 2020 Jul 5];68, Suppl S1:154-60. Available from: http://www.neurologyindia.com/text.asp?2020/68/7/154/287682




Pathology of the sella and its contents has always attracted medical and neurosurgical attention. Mass lesions in this small space produce focal, local, and distant effects. Locally they compress neural structures like the pituitary gland, the optic chiasm, and the brain. With increasing mass effect, they may compress the hypothalamus and the ventricular system, rarely leading to hydrocephalus. More commonly and importantly, they may disturb the hormonal balance as the anterior and posterior pituitary gland produce and control several hormonal systems in the body.

Surgical treatment for mass lesions with the aim of decompressing neural tissue as well as correcting hypersecretion of hormones (functional pituitary adenoma) is a well-established paradigm. Tumours of this region may also cause hypofunction of the hormonal axes and in addition to the surgical decompression, they may need endocrinological support. The overwhelming majority of sellar pathology are pituitary adenomas (>90%).[1],[2] Though much literature is available for this pathology, we need to be aware of the other less common sellar pathologies which need consideration during diagnosis and management. Cystic sellar lesions like arachnoid cysts, metastatic tumors, and rare pathologies like lymphoma, paragangliomas, germinoma and Langerhans cell histiocytosis (LCH) in children are well-known lesions with characteristic clinical and radiological features.[3],[4],[5],[6],[7],[8],[9] To complete the list, vascular lesions like aneurysms[10] and cavernous angiomas may also be rarely encountered in the sellar region.

Craniopharyngiomas can occasionally present as only a sellar lesion (10%) especially in pediatric patients.[11] Calcification and the cystic nature of the lesion are characteristic imaging findings and in most of these entities, the pituitary gland can be separately identified. Some infrequently encountered lesions within the parenchyma of the pituitary are the Rathke's cleft cyst and hypophysitis and are discussed here.

Rathke cleft cyst

The development of pituitary gland begins in the 4th week of intrauterine life. An evagination develops from the stomodeal epithelium, the Rathke pouch. The eponymous structure was postulated by Professor Martin Rathke in 1839. The Rathke pouch meets a projection from the diencephalon, which goes on to form the posterior pituitary or the neurohypophysis. Between the sixth and eighth week of development, the Rathke pouch separates from the oral epithelium. The adenohypophysis and the pars intermedia form from the pouch. The fully developed pituitary gland is found in the sella with the stalk which is essentially an extension of the third ventricle floor. The pituitary gland itself is made of the anterior lobe or the adenohypophysis, the posterior lobe of the neurohypophysis. After the formation of the anterior and posterior lobes, the cleft between them is the Rathke cleft.[12]

The Rathke Cleft Cyst (RCC) arises from the remnants of the Rathke cleft cells, in the pars intermedia of the pituitary gland. Incidental Rathke cleft cysts are known and several autopsy series demonstrate the presence of these.[13] Symptomatic cysts are not too common. A meta-analysis in 2014 collected less than 2,000 symptomatic cases reported in literature till then.[14],[15]

There is some variation in the types of cells lining the cyst. Ciliated cuboidal to columnar cells, which may contain goblet cells may be seen. The contents are usually mucinous in nature.[13] Occasionally, the contents may be solid because of inspissated material. There are the occasional case reports of calcification seen within the cyst.[16],[17] Symptomatic cysts enlarge and compress the surrounding structures. Thus, apart from diaphragmatic stretch and compressive clinical features of the visual apparatus, endocrinologic dysfunction may also be part of the clinical picture.[17],[18],[19]

Clinical features

Headache is the most common presenting symptom for symptomatic RCC (55%) Visual compromise due to direct compression of the optic nerves and chiasm is seen in many cases (34%).[14] Endocrinological dysfunction is seen in many asymptomatic patients (46%) Presentation like pituitary apoplexy is rarely reported. However, the severity of symptoms in this scenario are milder than a pituitary apoplexy. In our review of 58 cases (27 surgically operated) of RCC, 92% presented with headaches, 26% had visual symptoms, and 48% had hormonal dysfunction.[19]

Investigations

The 3 components of sellar pathology evaluation i.e., imaging, visual examination, and endocrinological evaluation are followed for RCC as well.

The imaging modality of choice is the MRI. RCC is commonly seen as an isointense lesion on T1 and hyperintense lesion on T2 imaging. Hypointensity on T2 indicates inspissated material within the cyst. The location of the cyst may be sellar, sellar suprasellar or purely suprasellar. There is an imaging classification[20] from Ozoner et al., which correlates the imaging characteristics viz. intensity, location of the cyst in the sagittal plane, with the possible approach needed and the outcomes. The normal pituitary is usually seen around the cyst and is identified by the enhancement pattern of the normal gland. the pituitary stalk is usually not displaced to one side as one would expect in a pituitary adenoma [Figure 1]. Contrast enhancement in an RCC wall may indicate inflammation or a squamous metaplasia. Diagnosing RCC is not always straightforward as it may be mistaken for a pituitary adenoma with apoplexy or a craniopharyngioma.[21],[22],[23],[24],[25],[26],[27],[28] There are reports of coexisting pituitary adenomas and other pathology with RCC. In our experience, the imaging diagnosis was accurate in seventy percent of cases for RCC. The other possibilities included pituitary adenoma with apoplexy and craniopharyngiomas.
Figure 1: Rathke cleft cyst: 35 yr. old male presented with headache and visual blurring. (a) sagittal T1 image of a Rathke cleft cyst showing as a sellar and suprasellar lesion. Note the posterior pituitary is seen as a hyperintense signal (bright spot) at the back of the sella. (b) the coronal FLAIR view shows the lesion to be isointense. Seen within the lesion is an area of Hypointensity, signifying denser, inspissated material. (c) contrast enhanced images show a faint homogenous enhancement. The normal pituitary gland is identified as a rim of uniformly enhancing tissue

Click here to view


Ophthalmologic evaluation involves visual acuity and visual fields charting. These were affected in 26% of our patients. The most common deficit was a bitemporal hemianopia.

Hormonal evaluation is mandatory as hormonal status may be altered in many patients. In our series, forty eight percent patients had hormonal dysfunction. Though hypopituitarism was the most expected dysfunction, moderate hyperprolactinemia (probably due to stalk effect) was the most common abnormality in our patients.

Treatment

Many RCC are asymptomatic and may be observed and evaluated at regular intervals. Symptomatic RCC, however, will need treatment. The principles of treatment are excision whenever possible. If the capsule is very flimsy, or very adherent, surgical decompression and adequate marsupialization of the cyst is performed to prevent recollection and recurrence as well as to avoid major pituitary dysfunction.[15],[29],[30]

This can be achieved by the transsphenoidal approach or by a craniotomy. With recent refinements in technique, the endonasal endoscopic approach has been our preferred path for surgery. Craniotomy and deroofing is rarely required and is reserved for large suprasellar extension[31] and was not necessary in any of our patients.

During the surgery, complete removal of the wall was thought to be an endpoint. However numerous reports now indicate that this may not be necessary from the point of alleviating the symptoms caused by the cyst. Surgical treatment brings about resolution of headache in most patients and vision improvement is seen in a sizeable number of patients.[14],[30],[32] Endocrinological recovery is not predictable and most patients remain stable or improve. Our series showed endocrine function improvement in 46% and a deterioration in 7%.[19] Cauterization of the cyst wall with absolute alcohol has been tried without significant benefit to prevent recurrence with increase in complications.[33]

The chief morbidity following transsphenoidal surgical treatment of RCC is CSF leak in the postoperative period and transient, endocrine worsening. The other important sequel to watch for over a long follow up is the recurrence of the cyst. The rates of cyst recurrence can be as high as 30%.[14] We have had only 1 recurrence in an incompletely removed cyst, 2 years after initial transsphenoidal procedure and a complete excision could be achieved during the second surgery. Certain factors like squamous metaplasia, a CSF leak at surgery and inflammation on histopathology features seem to be putative factors for reaccumulation within the cyst and recurrence.[30],[34],[35],[36] The microsurgical transsphenoidal approach was found to have a higher recurrence rate (14% vs. 8%) and new endocrine dysfunction rate (25% vs. 10%) compared to the endoscopic approach.[14] A novel method of lining the cavity with free mucosal flap has been described by Kuan et al.[37]

The most significant factor for recurrence in a recent review has been shown to be a residual disease at follow-up scan.[38] Thus, follow up to needs to be prolonged as recurrences are seen up to 5 years after successful surgery for the RCC, especially in this high risk group with residual cyst wall. Symptomatic lesions need to be treated with repeat surgery. Of interest is the use of drug eluting stents to prevent blocking off the opening of the opening created.[39] There also a report of stereotactic radiation therapy given to a small cohort of patients with more than one relapse with equivocal results.[40]

Hypophysitis

Hypophysitis may be defined as an acute or chronic inflammation of the pituitary gland with attendant pituitary hormonal dysfunction which may be associated with features of mass effect on the sellar and juxta sellar contents.

Traditionally hypophysitis has been classified according to a.) location involving the adenohypophysis, the infundibulum and posterior pituitary. The next classification paradigm has been b.) histopathology either lymphocytic/granulomatous/xanthomatous/necrotizing and more recently, the IgG4 related subtype has been added. The third paradigm is c.) etiologic classification viz. Primary hypophysitis or secondary to a systemic disease or drug administration.[41]

Primary hypophysitides are thought to have autoimmune origins and include lymphocytic hypophysitis, the most common type reported.[42] This is characterized by infiltration of the pituitary with lymphocytes and likely progresses to pituitary fibrosis. Several anti-pituitary antibodies have been described to initiate the process.[43]

Xanthomatous hypophysitis is the least common variety. This is thought to be on the continuum of the autoimmune spectrum. Recently, this entity is thought to be secondary to an inflammatory process like RCC rupture.[44] This would push this entity as a secondary hypophysitis.[42]

Granulomatous hypophysitis may be a primary hypophysitis or secondary to another pathology. The diagnosis thus a process of exclusion. Diseases like tuberculosis, sarcoidosis, histiocytosis and syphilis may incite hypophysitis which would be a secondary form. Rarely pituitary lymphoma may present as hypophysitis.[24],[45] Tuberculosis as a cause of granulomatous hypophysitis is a recognized etiology, especially in the Indian subcontinent and in areas of endemicity for tuberculosis and must be considered when assessing hypophysitis.[46],[47],[48],[49],[50],[51]

Newer forms of hypophysitis described are IgG4, ICI (Immune checkpoint inhibition) agents ipilimumab-related.[42],[52],[53],[54] The anti pit1 antibody syndrome, a cytotoxic T-cell mediated autoimmune disease can also cause hypophysitis.[43]

Clinical features

Primary hypophysitides are more common in female patients. There is association with pregnancy especially for lymphocytic varieties. Most patients are premenopausal [Figure 2]. However, more and more patients are being detected beyond the reproductive years.[55]
Figure 2: Lymphoid Hypophysitis. This 32 yr old female presented with increasing headaches and menstrual irregularity. She had mild hyperprolactinemia and hypocortisolemia apart from raised ESR and no other hormonal dysfunction. (a) shows a intensely enhancing sellar lesion without visualization of the normal pituitary. As she was not responding to medical treatment, a biopsy and limited decompression was performed showing Lymphoid Hypophysitis. On a follow up scan, three months later, there is significant resolution of the disease process as seen in (b). She had improvement in her hormonal profile and conceived shortly thereafter

Click here to view


The most common symptom is headache and endocrine dysfunction. Other symptoms may include visual compression.

The most common endocrinologic dysfunction is the adrenal insufficiency and hyperprolactinemia, seen in lymphocytic hypophysitis. Adrenocorticotropic hormone deficiency is almost always seen in lymphocytic hypophysitis. Granulomatous hypophysitis defects include posterior pituitary dysfunction in addition to headache.[56] In the xanthomatous variety, gonadotrophic and growth hormone deficiencies are also seen.[57] The IgG4 variant shows diabetes insipidus (DI) in nearly half of the patients.[54]

In secondary hypophysitis endocrinologic presentation depends on the specific etiology. Langerhans cell histiocytosis (LCH) presents with diabetes insipidus and a mild anterior pituitary dysfunction.

Diagnosis

The imaging modality of choice is the MRI with gadolinium enhancement. MRI shows an enlarged gland, which enhances variably. The thickened, enhancing, non-displaced pituitary stalk is the commonest feature. In patients with DI, the posterior bright spot is lost. The pituitary gland cannot be seen separately. Even so, in a significant number of cases, hypophysitis is misread as a pituitary adenoma. The MRI scoring system developed by Gutenberg et al. shows a high specificity and sensitivity to distinguish these entities. Their group found that the pregnant state, pituitary volume, gland symmetry, the signal intensity and homogeneity on contrast, the posterior pituitary bright spot, enlargement of the stalk, and sphenoidal mucosal swelling as significant factors for predicting hypophysitis over a pituitary adenoma. These were assigned a signed number based on statistical analysis that ranged from -13 to + 8. Scores of -13 to -2 were suggestive of hypophysitis, while scores of -2 to -8 suggested non-secreting pituitary adenomas.[58]

The sine qua non of diagnosis is histopathology. Lymphocyte infiltration, presence of macrophages, foamy histiocytes, (xanthomatous variety), multinucleated giant cells. This necessitates surgical exploration. Even before this, other diagnostic modalities include imaging, visual examination, and hormonal evaluation.[42],[48],[59] [Figure 3].
Figure 3: Granulomatous Hypophysitis. 45 yrs lady presented with intractable headaches. (a) Shows the T1 plain (on the left) and contrast enhanced coronal images (on the right). Note the intense homogenous contrast enhancement. Also note the indentation of the chiasm. Clinically, this doctor had a field defect and hypocortisolemia and hyperprolactinemia (stalk effect). In view of progressive symptoms on steroid therapy, she was operated by the transnasal endoscopic route. (b) shows a yellowish, firm consistency lesion. Biopsy revealed a granulomatous hypophysitis. Post-surgery, the visual complaints improved as did the hyperprolactinemia. She requires regular glucocorticoid supplements

Click here to view


Treatment

Treatment is directed toward reducing the inflammatory/immune response and the symptomatic mass effect caused due to the disease. Management of hormonal imbalances is an important component of treatment. Glucocorticoids play an important role to suppress and control the inflammatory process. Other immune suppressing agents like azathioprine and agents like rituximab have been used for treatment.[60],[61] Surgical treatment is reserved for those patients who do not respond to medical therapy, when the diagnosis is in doubt or when there is significant mass effect on the visual apparatus. Surgery usually involves a transnasal transsphenoidal approach and biopsy and decompression when needed.

Experience with hypophysitis in a neurosurgical unit

We have had the occasion to treat thirty eight cases of hypophysitis in the past twenty two years (1998-2020). Of over a 1,000 cases of sellar suprasellar pathology reviewed, 38 cases of hypophysitis were identified. Of these, 21 were treated conservatively. A total of 17 cases underwent surgical procedures. Of the operated cases, a vast majority (13/17) were female, and 9 of these 13 were premenopausal. The main indications for surgery here were optic apparatus compromise (9/17), progression of lesions despite medical treatment, persistent headaches (12/17) and uncertain diagnosis [Table 1].
Table 1: Clinical features of surgically treated hypophysitis (n=17)

Click here to view


Endocrine dysfunction [Table 2] was found in 13 of 17 patients. Adrenal axis hypofunction was seen in 8/13 patients, while diabetes insipidus was seen in 7/13 of these patients. Three patients had panhypopituitarism.
Table 2: Hormonal Involvement (n=13)

Click here to view


Interestingly, neuroimaging findings [Table 3] showed 7 patients as hypophysitis, while 10 were diagnosed as having a pituitary adenoma. The reason for this may be greater awareness and the long period of the study where radiological understanding and codification has improved in the latter half of the study period.
Table 3: Imaging features

Click here to view


All surgeries were done via the transnasal route [Table 4]. Three were done by endoscope assisted microsurgery, in the earlier part of the series. Of the operated cases, 10 were lymphocytic variety, while 7 were granulomatous. Of the granulomatous variety, 2 were tuberculous granulomas. No xanthomatous variant was encountered [Figure 4].
Table 4: Surgery features for hypophysitis

Click here to view
Figure 4: Tuberculous hypophysitis. This 38 year old male patient presented with Addisonian crisis. MRI suggestive of a cystic pituitary lesion, (a), with peripheral enhancement (b). The contrast image shows a thickened stalk. Though he initially improved with steroids, his symptoms (visual), progressed and he was operated. The histopathology turned out to be tuberculous hypophysitis. The gelatinous fluid from the lesion showed a growth of M. tuberculosis

Click here to view


Postoperative results showed significant relief of headache (91.6%), and improvement in vision in 88% of patients. Hormone function improved in 6 of the 13 patients. There was worsening in 2 patients, while 5 had unchanged hormone functions. CSF leak was seen in 3 postoperative patients. Two of these needed a lumbar drain inserted for 2 days to control the leak. To summarize our experience, as well as the evidence from literature, surgical exploration has specific indications and can be done safely via the trans sphenoid endoscopic method. In our setting, it is especially important to look for tuberculous hypophysitis.


 » Conclusions Top


Although the most common sellar pathology is the pituitary adenoma, attention must be drawn to the other possibilities. This can be due to odd history, atypical hormonal disturbance or atypical imaging features. A detailed interaction with endocrinologist is necessary and medical treatment can relieve this condition in most of these patients. Surgery has a limited role only for proper diagnosis and decompression may become necessary in a few cases. The outcomes from treatment, especially surgical treatment, would depend on high index of suspicion (as non-adenoma lesions) and recognition early during the surgery, resulting in appropriate management.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Huang BY, Castillo M. Nonadenomatous tumors of the pituitary and sella turcica. Top Magn Reson Imaging 2005;16:289-99.  Back to cited text no. 1
    
2.
Koutourousiou M, Kontogeorgos G, Seretis A. Non-adenomatous sellar lesions: Experience of a single centre and review of the literature. Neurosurg Rev 2010;33:465-76.  Back to cited text no. 2
    
3.
Abele TA, Yetkin ZF, Raisanen JM, Mickey BE, Mendelsohn DB. Non-pituitary origin sellar tumours mimicking pituitary macroadenomas. Clin Radiol 2012;67:821-7.  Back to cited text no. 3
    
4.
Dutta G, Singh D, Singh H, Srivastava AK, Jagetia A, Sachdeva D. Pituitary fossa chondrosarcoma: An unusual cause of a sellar suprasellar mass masquerading as pituitary adenoma. Surg Neurol Int 2018;9:76.  Back to cited text no. 4
  [Full text]  
5.
Ferreira AG, Silva TN, Luiz HV, Campos FD, Cordeiro MC, Portugal JR. Sellar plasmacytoma presenting with symptoms of anterior pituitary dysfunction. Endocrinol Diabetes Metab Case Rep 2017;2017: 17-0102.  Back to cited text no. 5
    
6.
Güdük M, HamitAytar M, Sav A, Berkman Z. Intrasellar arachnoid cyst: A case report and review of the literature. Int J Surg Case Rep 2016;23:105-8.  Back to cited text no. 6
    
7.
Hernández-Estrada RA, Kshettry VR, Vogel AN, Curtis MT, Evans JJ. Cholesterol granulomas presenting as sellar masses: A similar, but clinically distinct entity from craniopharyngioma and Rathke's cleft cyst. Pituitary 2017;20:325-32.  Back to cited text no. 7
    
8.
Salvatore B, D'Amico D, Fonti R. Metastasis to the sellar/suprasellar region in a patient with endometrial carcinoma detected by 18F-FDG PET/CT. Clin Nucl Med 2018;43:363-4.  Back to cited text no. 8
    
9.
Yang X, Liu X, Li W, Chen D. Pituicytoma: A report of three cases and literature review. Oncol Lett 2016;12:3417-22.  Back to cited text no. 9
    
10.
Jagetia A, Patel K, Sachdeva D, Rathore L. Dolichoectatic internal carotid artery presenting as a sellar-suprasellar mass with symptomatic hydrocephalus. Neurol India 2017;65:681-2.  Back to cited text no. 10
[PUBMED]  [Full text]  
11.
Jagannathan J, Dumont AS, Jane JA, Laws ER. Pediatric sellar tumors: Diagnostic procedures and management. Neurosurg Focus 2005;18:1-5.  Back to cited text no. 11
    
12.
Amar AP, Weiss MH. Pituitary anatomy and physiology. Neurosurg Clin N Am 2003;14:11-23.  Back to cited text no. 12
    
13.
Byun WM, Kim OL, Kim D. MR imaging findings of Rathke's cleft cysts: Significance of intracystic nodules. Am J Neuroradiol 2000;21:485-8.  Back to cited text no. 13
    
14.
Mendelson ZS, Husain Q, Elmoursi S, Svider PF, Eloy JA, Liu JK. Rathke's cleft cyst recurrence after transsphenoidal surgery: A meta-analysis of 1151 cases. J Clin Neurosci 2014;21:378-85.  Back to cited text no. 14
    
15.
Mendelson ZS, Husain Q, Kanumuri VV, Eloy JA, Liu JK. Endoscopic transsphenoidal surgery of Rathke's cleft cyst. J Clin Neurosci 2015;22:149-54.  Back to cited text no. 15
    
16.
Hayashi Y, Oishi M, Fukui I, Sasagawa Y, Harada KI, Nakada M. Rathke cleft cyst with entirely ossified cyst wall and partially solid cyst content: A case report and literature review. World Neurosurg 2017;98:882.e15-882.e20.  Back to cited text no. 16
    
17.
Zada G. Rathke cleft cysts: A review of clinical and surgical management. Neurosurg Focus 2011;31:E1.  Back to cited text no. 17
    
18.
Sasaki Yatabe M, Watanabe K, Hayashi Y, Yatabe J, Morimoto S, Ichihara A, et al. Overlap of post-obstructive diuresis and unmasked diabetes insipidus in a case of IgG4-related retroperitoneal fibrosis and tuberoinfundibular hypophysitis: A case report and review of the literature. Intern Med 2017;56:47-53.  Back to cited text no. 18
    
19.
Ratha V, Patil S, Karmarkar VS, Shah NJ, Deopujari CE. Surgical management of Rathke cleft cysts. World neurosurg 2017;107:276-84.  Back to cited text no. 19
    
20.
Ozoner B, Aydin S, Akgun MY, Durmaz ES, Sahin S, Gazioglu N, et al. Predictive factors for Rathke's cleft cyst consistency. World Neurosurg 2019;128:e522-30.  Back to cited text no. 20
    
21.
Zamora C, Castillo M. Sellar and Parasellar imaging. Neurosurgery 2017;80:17-38.  Back to cited text no. 21
    
22.
Wu W, Jia G, Jia W, Li G, Zhang J, Zhang L. Pituitary adenoma associated with Rathke's cleft cyst: Report of 15 cases. Can J Neurol Sci 2018;45:68-75.  Back to cited text no. 22
    
23.
Wang S, Nie Q, Wu Z, Zhang J, Wei L. MRI and pathological features of Rathke cleft cysts in the sellar region. Exp Ther Med 2020;19:611-8.  Back to cited text no. 23
    
24.
Martinez JH, Davila Martinez M, Mercado de Gorgola M, Montalvo LF, Tome JE. The coexistence of an intrasellar adenoma, lymphocytic hypophysitis, and primary pituitary lymphoma in a patient with acromegaly. Case Rep Endocrinol 2011;2011:941738.  Back to cited text no. 24
    
25.
Kitai R, Yamauchi T, Arai Y, Hosoda T, Hashimoto N, Tsunetoshi K, et al. Deflation of a Rathke cleft cyst triggered rupture of a superior hypophyseal artery aneurysm: A case report. Br J Neurosurg 2019;33:219-21.  Back to cited text no. 25
    
26.
Jung HN, Kim ST, Kong DS, Suh SI, Ryoo I. Rathke cleft cysts with apoplexy-like symptoms: Clinicoradiological comparisons to pituitary adenomas with apoplexy. World Neurosurg 2020;S1878-8750 (20) 30557-X. doi: 10.1016/j.wneu. 2020.03.086.  Back to cited text no. 26
    
27.
Hayashi Y, Kita D, Fukui I, Sasagawa Y, Oishi M, Okajima M, et al. Pediatric symptomatic Rathke cleft cyst compared with cystic craniopharyngioma. Childs Nerv Syst 2016;32:1625-32.  Back to cited text no. 27
    
28.
de Almeida Verdolin A, Lamback EB, Ventura N, Guasti A, da Mata Pereira PJ, Gadelha MR, et al. Collision sellar lesions: Coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience. Endocrine 2020;68:174-81.  Back to cited text no. 28
    
29.
Benveniste RJ, King WA, Walsh J, Lee JS, Naidich TP, Post KD. Surgery for Rathke cleft cysts: Technical considerations and outcomes. J Neurosurg 2004;101:577-84.  Back to cited text no. 29
    
30.
Han SJ, Rolston JD, Jahangiri A, Aghi MK. Rathke's cleft cysts: Review of natural history and surgical outcomes. J Neurooncol 2014;117:197-203.  Back to cited text no. 30
    
31.
Fan J, Peng Y, Qi S, Zhang X, Qiu B, Pan J. Individualized surgical strategies for Rathke cleft cyst based on cyst location. J Neurosurg 2013;119:1437-46.  Back to cited text no. 31
    
32.
Altuwaijri N, Cote DJ, Lamba N, Albenayan W, Ren SP, Zaghloul I, et al. Headache resolution after Rathke cleft cyst resection: A meta-analysis. World Neurosurg 2018;111:e764-72.  Back to cited text no. 32
    
33.
Lillehei KO, Widdel L, Astete CAA, Wierman ME, Kleinschmidt-DeMasters BK, Kerr JM. Transsphenoidal resection of 82 Rathke cleft cysts: Limited value of alcohol cauterization in reducing recurrence rates. J Neurosurg 2011;114:310-7.  Back to cited text no. 33
    
34.
Chotai S, Liu Y, Pan J, Qi S. Characteristics of Rathke's cleft cyst based on cyst location with a primary focus on recurrence after resection. J Neurosurg 2015;122:1380-9.  Back to cited text no. 34
    
35.
Kinoshita Y, Tominaga A, Usui S, Arita K, Sakoguchi T, Sugiyama K, et al. The long-term recurrence of Rathke's cleft cysts as predicted by histology but not by surgical procedure. J Neurosurg 2016;125:1002-7.  Back to cited text no. 35
    
36.
Lin M, Wedemeyer MA, Bradley D, Donoho DA, Fredrickson VL, Weiss MH, et al. Long-term surgical outcomes following transsphenoidal surgery in patients with Rathke's cleft cysts. J Neurosurg 2018;130:831-7.  Back to cited text no. 36
    
37.
Kuan EC, Yoo F, Chyu J, Bergsneider M, Wang MB. Treatment outcomes of Rathke's cleft cysts managed with marsupialization. J Neurol Surg B Skull Base 2017;78:112-5.  Back to cited text no. 37
    
38.
Marcus HJ, Borg A, Hussein Z, Jaunmuktane Z, Baldeweg SE, Grieve J, et al. Rathke's cleft cysts following transsphenoidal surgery: Long-term outcomes and development of an optimal follow-up strategy. Acta Neurochir (Wien) 2020;162:853-61.  Back to cited text no. 38
    
39.
Wong AK, Raviv J, Ciric I, Wong RH. Novel use of biodissolvable stent in treatment of recurrent Rathke cleft cyst. World Neurosurg 2019;131:186-90.  Back to cited text no. 39
    
40.
Agarwalla PK, Koch MJ, Royce TJ, Redjal N, Bussière MR, Loeffler JS, et al. Stereotactic radiation as salvage therapy for recurrent Rathke cleft cysts. Neurosurgery 2020:nyz523. doi: 10.1093/neuros/nyz523.  Back to cited text no. 40
    
41.
Fukuoka H. Hypophysitis. Endocrinol Metab Clin North Am 2015;44:143-9.  Back to cited text no. 41
    
42.
Angelousi A, Alexandraki KI, Tsoli M, Kaltsas G, Kassi E. Hypophysitis (including IgG4 and immunotherapy). Neuroendocrinology 2020. doi: 10.1159/000506903.  Back to cited text no. 42
    
43.
Yamamoto M, Iguchi G, Takeno R, Okimura Y, Sano T, Takahashi M, et al. Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest 2011;121:113-9.  Back to cited text no. 43
    
44.
Yang C, Wu H, Bao X, Wang R. Lymphocytic hypophysitis secondary to ruptured Rathke cleft cyst: Case report and literature review. World Neurosurg 2018;114:172-7.  Back to cited text no. 44
    
45.
Huang YY, Lin SF, Dunn P, Wai YY, Hsueh C, Tsai JS. Primary pituitary lymphoma presenting as hypophysitis. Endocr J 2005;52:543-9.  Back to cited text no. 45
    
46.
Arunkumar MJ, Rajshekhar V. Intrasellar tuberculoma presenting as pituitary apoplexy. Neurol India 2001;49:407-10.  Back to cited text no. 46
[PUBMED]  [Full text]  
47.
Ates I, Katipoglu B, Copur B, Yilmaz N. A rare cause of hypophysitis: Tuberculosis. Endocr Regul 2017;51:213-5.  Back to cited text no. 47
    
48.
Hunn BHM, Martin WG, Simpson S, Mclean CA. Idiopathic granulomatous hypophysitis: A systematic review of 82 cases in the literature. Pituitary 2014;17:357-65.  Back to cited text no. 48
    
49.
Husain N, Husain M, Rao P. Pituitary tuberculosis mimicking idiopathic granulomatous hypophysitis. Pituitary 2008;11:313-5.  Back to cited text no. 49
    
50.
Singh S. Pituitary tuberculoma: Magnetic resonance imaging. Neurol India 2003;51:548-50.  Back to cited text no. 50
  [Full text]  
51.
Sunil K, Menon R, Goel N, Sanghvi D, Bandgar T, Joshi SR, et al. Pituitary tuberculosis. J Assoc Physicians India 2007;55:453-6.  Back to cited text no. 51
    
52.
Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A, et al. Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 2014;99:4078-85.  Back to cited text no. 52
    
53.
Leporati P, Landek-Salgado MA, Lupi I, Chiovato L, Caturegli P. IgG4-related hypophysitis: A new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 2011;96:1971-80.  Back to cited text no. 53
    
54.
Wong S, Lam WY, Wong WK, Lee KC. Hypophysitis presented as inflammatory pseudotumor in immunoglobulin G4-related systemic disease. Hum Pathol 2007;38:1720-3.  Back to cited text no. 54
    
55.
Menon SK, Sarathi V, Bandgar TR, Menon PS, Goel N, Shah NS. Autoimmune hypophysitis: A single centre experience. Singapore Med J 2009;50:1080-4.  Back to cited text no. 55
    
56.
Imga NN, Yildirim AE, Baser OO, Berker D. Clinical and hormonal characteristics of patients with different types of hypophysitis: A single-center experience. Arch Endocrinol Metab 2019;63:47-52.  Back to cited text no. 56
    
57.
Gutenberg A, Hans V, Puchner MJA, Kreutzer J, Brück W, Caturegli P, et al. Primary hypophysitis: Clinical-pathological correlations. Eur J Endocrinol 2006;155:101-7.  Back to cited text no. 57
    
58.
Gutenberg A, Larsen J, Lupi I, Rohde V, Caturegli P. A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively. AJNR Am J Neuroradiol 2009;30:1766-72.  Back to cited text no. 58
    
59.
Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in endocrinology: Hypophysitis: diagnosis and treatment. Eur J Endocrinol 2018;179:R151-63.  Back to cited text no. 59
    
60.
Schreckinger M, Francis T, Rajah G, Jagannathan J, Guthikonda M, Mittal S. Novel strategy to treat a case of recurrent lymphocytic hypophysitis using rituximab. J Neurosurg 2012;116:1318-23.  Back to cited text no. 60
    
61.
Chiloiro S, Tartaglione T, Capoluongo ED, Angelini F, Arena V, Giampietro A, et al. Hypophysitis outcome and factors predicting responsiveness to glucocorticoid therapy: A prospective and double-arm study. J Clin Endocrinol Metab 2018;103:3877-89.  Back to cited text no. 61
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow